- 1 Also known as
- 2 Classification
- 3 Overview
- 4 Medical usage
- 5 What does it look like?
- 6 Dosage
- 7 How long do its effects last?
- 8 Pharmacology
- 9 Effects
- 10 Risks
- 11 Addiction
- 12 Interactions
- 13 References
Also known as
Suggested uses are urethane catalyst, textile softeners, pH control, and epoxy resin curing agents .
MDEA currently has no accepted medical uses 
What does it look like?
Clear, colourless or yellow liquid without any mechanical impurities .
- threshold - 50 - 70 mg,
- light - 70 - 120 mg , 80 - 100 mg ,
- common - 120 - 180 mg , 100 - 150 mg ,
- strong - 180 - 225 mg , 150 - 200 mg ,
- heavy - 225 mg + .
How long do its effects last?
Onset of effects
- oral - 20 - 60 minutes .
- all ROA's - 30 - 60 minutes .
- oral - 140 mg - 20 - 85 minutes ,
- oral - 160 mg - 40 minutes .
- oral - 15 - 30 minutes .
- oral - 90 - 120 minutes .
- oral - 1 - 2 hours .
Duration of effects
- oral - 3 - 5 hours .
- all ROA's - 3 - 6 hours ,
- oral - 140 mg - 2 - 3 hours ,
- oral - 160 mg - 3 - 5 hours .
- oral - 12 - 48 hours .
MDEA has been shown to act as a releasing agent and reuptake inhibitor of the key monoamine neurotransmitters serotonin, dopamine and noradrenaline , which are the neurotransmitters responsible for modulating focus, motivation, pleasure, and reward. This is done by inhibiting the reuptake and reabsorption of monoamine neurotransmitters after they have performed their function of transmitting a neural impulse, allowing them to accumulate in the synaptic cleft and be reused in a manner which causes physically stimulating, sedating, disinhibiting and euphoric effects . The often-reported "stoning" effects have been theorised to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.
It has also been noted that MDEA, even at lower doses, stimulates the release of oxytocin and prolactin, two hormones that are currently being studied for their potential roles in modulating the feeling of trust and love , .
Route of administration
MDEA is usually taken orally, rarely nasally or as a suppository. As amines, all RSAs are soluble in water and alcohol , , and can, therefore, be injected. Their inhalation as a vapour is impossible due to their high boiling points .
On the basis of acute studies with laboratory animals, methyldiethanolamine is considered slightly toxic by single oral dose and practically nontoxic by single dermal application .
Tolerance to many of the effects of MDEA develops with prolonged and repeated use. This results in users having to administer increasingly larger doses to achieve the same effects. After that, it takes about 1 - 1.5 months for the tolerance to be reduced to half and 2 - 3 months to be back at baseline (in the absence of further consumption). MDEA presents cross-tolerance with all dopaminergic and serotonergic stimulants and entactogens, meaning that after the consumption of MDEA all of these will have a reduced effect .
- physical euphoria,
- pupil dilation,
- spontaneous physical sensations,
- bodily control enhancement,
- perception of bodily heaviness,
- stamina enhancement,
- tactile enhancement,
- appetite suppression,
- brain zaps,
- difficulty urinating,
- increased blood pressure,
- increased heart rate,
- increased perspiration,
- teeth grinding,
- temperature regulation suppression,
- temporary erectile dysfunction .
- cognitive euphoria,
- compulsive redosing,
- time distortion,
- creativity enhancement,
- dream potentiation,
- empathy, affection and sociability enhancement,
- focus enhancement,
- immersion enhancement,
- increased libido,
- increased music appreciation,
- motivation enhancement,
- stamina enhancement,
- thought acceleration,
- anxiety suppression,
- cognitive fatigue,
- dream suppression,
- motivation suppression,
- thought deceleration,
- existential self-realisation,
- unity and interconnectedness .
- colour enhancement,
- pattern recognition enhancement,
- symmetrical texture repetition,
- double vision,
- vibrating vision,
- peripheral information misinterpretation .
- auditory distortion,
- auditory enhancement,
- auditory hallucinations .
Reported overdose symptoms of MDEA include the following -
- disseminated intravascular coagulation,
- muscle rigidity,
- sweating .
Can you get addicted
As with other stimulants, the chronic use of MDEA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage .
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption .
- 25x-NBOMe - Both the NBOMe series and this compound induce powerful stimulation and their interaction may cause severe side-effects. These can include thought loops, seizures, increased blood pressure, vasoconstriction, increased heart rate, and heart failure (in extreme cases).
- Alcohol - It is dangerous to combine alcohol, a depressant, with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of alcohol which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of alcohol will be significantly increased, leading to intensified disinhibition as well as respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- DXM - This combination may cause increased heart rate and panic attacks.
- MXE - Increased heart rate and blood pressure may occur.
- Tramadol - This combination can increase the risk of seizures.
- MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, 2C-T-2, 2C-T-7, αMT, and some antidepressants .
- Stimulants - The neurotoxic effects of MDEA may be increased when combined with other stimulants.
- Cocaine - This combination may increase strain on the heart .
- Tramadol - Tramadol and stimulants both increase the risk of seizures.
- MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises .
- DOx - The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
- NBOMes - Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and in extreme cases heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
- 2C-T-x - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences. In extreme cases, they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
- 5-MeO-xxT - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these drugs have led to more serious heart issues.
- PCP - This combination can easily lead to hypermanic states .
- Huntsman Corporation, Methyldiethanolamine (MDEA), 2010, http://www.huntsman.com/portal/page/portal/C348531D1F3DA9A2E040EBCD2B6B7B06
- 3,4-Methylenedioxy-N-ethylamphetamine, 2017, https://en.wikipedia.org/wiki/34-Methylenedioxy-N-ethylamphetamine
- Methyldiethanolamine (MDEA), 2017, http://sintez-oka.com/eng/products/alkylethanolamines/mdea/
- MDEA, 2017, https://psychonautwiki.org/wiki/MDEA
- MDEA, 2017, http://drugs.tripsit.me/mdea
- Gouzoulis-Mayfrank, E. and Hermle, L. and Kovar, K. A. and Sass, H., Die Entaktogene "Ecstasy" (MDMA), "Eve" (MDE) und andere ringsubstituierte Methamphetaminderivate. Eine neue Stoffklasse unter den illegalen Designer-drogen?, Nervenarzt, 1996, 67, 369-380
- Shulgin, A. aShulgin, A., Phenethylamines I Have Known And Loved: A Chemical Love Story, 2015, https://www.erowid.org/library/books_online/pihkal/pihkal.shtml
- Freudenmann, R. W. and Spitzer, M., The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), CNS Drug Reviews, 2004, 10, 2, 89-116, https://org.doi/10.1111/j.1527-3458.2004.tb00007.x, http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/abstractjsessionid=DFEBB1CE08CA49F66D700DD8AF6666FE.f04t03
- Fleckenstein, A. E. and Volz, T. J. and Riddle, E. L. and Gibb, J. W. and Hanson, G. R., New Insights into the Mechanism of Action of Amphetamines, Annual Review of Pharmacology and Toxicology, 2007, 47, 681-698, https://doi.org/10.1146/annurev.pharmtox.47.120505.105140, http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140
- Passie, T., Healing with Entactogens: Therapist and Patient Perspectives on MDMA-Assisted Group Psychotherapy, 2012, Multidisciplinary Association for Psychedelic Studies (MAPS), ISBN 0979862272, 92, https://www.amazon.com/Healing-Entactogens-Perspectives-MDMA-Assisted-Psychotherapy/dp/0979862272
- Climko, R. P. and Roehrich, H. and Sweeney, D. R. and Al-Razi, J., Ecstasy: A review of MDMA and MDA, International Journal of Psychiatry in Medicine, 1986, 16, 4, 359-372, https://www.ncbi.nlm.nih.gov/pubmed/2881902
- Kalant, H., The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs, Canadian Medical Association Journal, 2001, 165, 7, 917-928, http://www.cmaj.ca/content/165/7/917.full
- Freudenmann, R. W. and Spitzer, M., The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), CNS Drug Reviews, 2004,10, 2, 89-116, http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf
- Tehan, B. and Hardern, R. and Bodenham, A., Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'), Anaesthesia, 1993, 48, 6, 507-510, http://dx.doi.org/10.1111/j.1365-2044.1993.tb07072.x
- Gouzoulis, E. and Borchardt, D. and Hermle, L., A case of toxic psychosis induced by 'eve' (3,4-methylene-dioxyethyl-amphetamine), Archives of General Psychiatry, 1993, 50, 75
- Hermle, L. and Spitzer, M. and Borchardt, D. and Kovar, K. A. and Gouzoulis, E., Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?, Neuropsychopharmacology, 1993, 8, 171-176
- Iwersen, S. and Schmoldt, A., Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam, Journal of Toxicology: Clinical Toxicology, 1996, 34, 241-244
- Vaiva, G. and Boss, V. and Bailly, D. and Thomas, P. and Lestavel, P. and Goudemand, M., An "accidental" acute psychosis with ecstasy use, Journal of Psychoactive Drugs, 2001, 33, 1, 95-98, https://doi.org/10.1080/02791072.2001.10400473, https://www.ncbi.nlm.nih.gov/pubmed/11333007
- Gillman, P. K., Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity, British Journal of Anaesthesia, 2005, 95, 4, 434-441, https://doi.org/10.1093/bja/aei210, https://www.ncbi.nlm.nih.gov/pubmed/16051647